Literature DB >> 1971448

Effects of single and repeated treatment with antidepressants on apomorphine-induced yawning in the rat: the implication of alpha-1 adrenergic mechanisms in the D-2 receptor function.

A Delini-Stula1, C Hunn.   

Abstract

Acute (10 or 20 mg/kg IP) and subchronic (2 x 5 or 10 mg/kg IP daily for 7 days) effects of desipramine, imipramine, maprotiline, (+)- and (-)-oxaprotiline enantiomers as well as selective 5-HT-uptake inhibitors citalopram and ifoxetine on yawning, induced by low doses of apomorphine, were investigated in the rat. In addition, the effects of alpha-1 receptor agonist adrafinil and antagonist prazosin were also tested. After acute treatment, desipramine, the stereoselective NA-uptake inhibiting (+)-enantiomer of oxaprotiline, and the alpha-1 agonist adrafinil, markedly and significantly suppressed yawning. Prazosin, in contrast, clearly potentiated it. This potentiating effect was abolished by the pretreatment with (+)-oxaprotiline and adrafinil. Other drugs were inactive. After subchronic administration, yawning was antagonized by NA-uptake-inhibiting antidepressants, including imipramine and maprotiline. By comparison to the acute treatment, the inhibitory effects of desipramine and (+)-oxaprotiline were considerably enhanced. Neither selective 5-HT-uptake inhibitors nor (-)-oxaprotiline (levoprotiline) were active. Antidepressants therefore modulate the functional activity of D-2 receptors, activated by low doses of apomorphine, predominantly by the virtue of their noradrenergic enhancing properties. This modulatory effect appears to be mediated by alpha-1 adrenergic receptors.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1971448     DOI: 10.1007/bf02253719

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  19 in total

1.  Progress in the psychopharmacology of antidepressants: selective uptake and MAO-inhibitors.

Authors:  A Delini-Stula
Journal:  Schweiz Arch Neurol Psychiatr (1985)       Date:  1986

2.  Antagonism of apomorphine-induced yawning by SCH 23390: evidence against the autoreceptor hypothesis.

Authors:  M Morelli; R Longoni; L Spina; G Di Chiara
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

3.  Oxaprotiline, a noradrenaline uptake inhibitor with an active and an inactive enantiomer.

Authors:  P C Waldmeier; P A Baumann; K Hauser; L Maitre; A Storni
Journal:  Biochem Pharmacol       Date:  1982-06-15       Impact factor: 5.858

4.  The influence of oxaprotiline enantiomers given repeatedly on the behavioural effects of d-amphetamine and dopamine injected into the nucleus accumbens.

Authors:  J Maj; K Wedzony
Journal:  Eur J Pharmacol       Date:  1988-01-12       Impact factor: 4.432

5.  A possibe alpha-adrenergic mechanism for drug (CRL 40028)-induced hyperactivity.

Authors:  J Duteil; F A Rambert; J Pessonnier; R Gombert; E Assous
Journal:  Eur J Pharmacol       Date:  1979-10-26       Impact factor: 4.432

6.  Yawning and suppression of exploration in amphetamine-treated rats, incompatibility with the autoreceptor hypothesis.

Authors:  L Ståhle; U Ungerstedt
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

7.  Desipramine induces yawning behaviour in rats.

Authors:  E Mogilnicka; K Wedzony; V Klimek; A Czyrak
Journal:  Neuropharmacology       Date:  1986-07       Impact factor: 5.250

8.  Dopamine receptors mediating yawning: are they autoreceptors?

Authors:  G Serra; M Collu; G L Gessa
Journal:  Eur J Pharmacol       Date:  1986-01-21       Impact factor: 4.432

9.  Direct evidence for involvement of dopaminergic inhibition and cholinergic activation in yawning.

Authors:  K Yamada; T Furukawa
Journal:  Psychopharmacology (Berl)       Date:  1980-01       Impact factor: 4.530

10.  Ifoxetine, a compound with atypical effects on serotonin uptake.

Authors:  P C Waldmeier; L Maître; P A Baumann; K Hauser; S Bischoff; H Bittiger; R Paioni
Journal:  Eur J Pharmacol       Date:  1986-10-14       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.